Pharma BD Deal Intelligence

Pierre Fabre Laboratories / XtalPi Holdings Ltd.

2026 · Co-Development · Complete

Laboratoires Pierre Fabre and XtalPi Holdings entered an AI-driven drug discovery collaboration spanning oncology and potentially dermatology and rare diseases. XtalPi will use its integrated AI and robotics platform to de novo design and deliver novel small-molecule therapeutics against undisclosed targets; Pierre Fabre contributes disease biology, discovery, translational research and clinical development expertise, selecting compounds and taking responsibility for subsequent clinical and commercial development. The agreement includes an upfront payment, multiple milestone payments and downstream economic participation; neither party disclosed financial terms.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →